Atropine Eyedrops Reduce Nearsightedness Incidence in Kids
(MedPage Today) -- Nightly use of 0.05% atropine eyedrops in kids led to a significantly lower incidence of myopia at 2 years, and a lower percentage with fast myopic shift, a randomized trial from Hong Kong showed.
Among children ages 4 to 9... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - February 15, 2023 Category: Pediatrics Source Type: news
Atropine Eyedrops Reduce Incidence of Nearsightedness Out to 2 Years
(MedPage Today) -- Nightly use of 0.05% atropine eyedrops in kids led to a significantly lower incidence of myopia at 2 years, and a lower percentage with fast myopic shift, a randomized trial from Hong Kong showed.
Among children ages 4 to 9... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - February 14, 2023 Category: Pediatrics Source Type: news
0.05 Percent Atropine Eye Drops Result in Lower Incidence of Myopia
TUESDAY, Feb. 14, 2023 -- Nightly use of 0.05 percent atropine eye drops compared with placebo results in a significantly lower incidence of myopia and a lower percentage of patients with fast myopic shift at two years among children aged 4 to 9... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 14, 2023 Category: Pharmaceuticals Source Type: news
Nigeria: Danger! Bitter Kola Eye Drops Won't Cure Glaucoma, Myopia and Other Eye Problems - See Doctor Instead
[Africa Check] IN SHORT: Our eyes are sensitive and easily damaged, which could lead to blindness. Don't put anything in your eyes that hasn't been approved by a qualified health professional. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - January 31, 2023 Category: African Health Source Type: news
A 26-year-old founded a medical startup
As a rifleman in the Republic of Korea Marine Corps who endured harsh training as part of his national service, Kevin Choi had "no doubt" about the state of his health. "I've got quite severe myopia, but I still believed I was very healthy," Choi told CNBC Make It. But all that changed in 2016,…#republicofkorea #kevinchoi #choi #mediwhale #tylerhyungtaekrim #rim #ct #korea #singapore #fda (Source: Reuters: Health)
Source: Reuters: Health - January 27, 2023 Category: Consumer Health News Source Type: news
Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Education Interacts With Genetic Variants to Increase Myopia Risk
TUESDAY, Nov. 22, 2022 -- Education interacts with genetic variants to confer susceptibility to myopia, according to a study published online Nov. 17 in PLOS Genetics.
Rosie Clark, Ph.D., from Cardiff University in the United Kingdom, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 22, 2022 Category: Pharmaceuticals Source Type: news
Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Myopia and depression among middle school students in China-is there a mediating role for wearing eyeglasses? - Huang J, Dang H, Cai Y, Liu J, Chen Q.
Compared with non-myopic students, myopic students face more barriers to learning (e.g., inability to see the blackboard clearly) and socializing (e.g., being victims of teasing, social exclusion and violence), which may lead to increased stress, anxiety a... (Source: SafetyLit)
Source: SafetyLit - October 31, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Th érèse Coffey is leaving the UK vulnerable to monkeypox | Ceri Smith
The vaccination programme for gay and bisexual men is simply not enough to protect against future outbreaksReports that new health secretary, Th érèse Coffey, has rejected her officials’ expert advice to procure an additional70,000 doses of monkeypox vaccine are deeply concerning and shortsighted.Less than a month into the role, Coffey is said to have gone against the recommendation of those who have been leading the country ’s response, and made a critical decision that leaves the UK vulnerable to future outbreaks of monkeypox.Comments on this piece are premoderated to ensure discussion remains on topics raised by t...
Source: Guardian Unlimited Science - October 4, 2022 Category: Science Authors: Ceri Smith Tags: Monkeypox Health policy érèse Coffey Conservatives Infectious diseases Politics Science World news UK news Society LGBTQ rights Source Type: news
U.K. Says No To Extra Monkeypox Vaccines: Report
The government says it has enough doses to meet current demand. But campaigners have called the move "shortsighted." (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 3, 2022 Category: Pharmaceuticals Authors: Katherine Hignett, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news
Phakic IOLs for Myopia and Myopic Astigmatism Phakic IOLs for Myopia and Myopic Astigmatism
This review provides an update on the currently available phakic intraocular lenses for the correction of myopia or myopic astigmatism.Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 30, 2022 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX ® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
LOS ANGELES, August 27, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study evaluating the investigational use of DARZALEX® (daratumumab) in combination with lenalidomide (Revlimid®), bortezomib (VELCADE®) and dexamethasone (DARZALEX®-RVd), followed by maintenance therapy with DARZALEX®-lenalidomide (R), compared to RVd followed by maintenance therapy with R alone, in patients with newly diagnosed, transplant-eligible multiple myeloma. Data were presented in the plenary session at the 19th International Myeloma Society (IMS)...
Source: Johnson and Johnson - August 28, 2022 Category: Pharmaceuticals Source Type: news
Children could suffer from long-term eye problems due to too much screen time
A third of children are spending more than five hours a day on their screens over the summer holidays - which could cause long-term eye damage, experts have warned. A study of 1,500 parents found four in ten were completely unaware that extended periods using gadgets, such as tablets or phones, can be a leading cause for eye problems, like myopia - commonly known as short-sightedness. (Source: Daily Express - Health)
Source: Daily Express - Health - August 24, 2022 Category: Consumer Health News Source Type: news
Oral Supplement for Childhood Myopia: Preliminary Data Promising
(MedPage Today) -- Oral intake of 7-methylxanthine (7-MX) was associated with reduced myopia progression and axial elongation in children, according to a retrospective study from Denmark, where the caffeine metabolite is authorized for myopia control... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 24, 2022 Category: Pediatrics Source Type: news
